Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

NIH Tetramer Core Facility

Active
75N93026R00006Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This solicitation, issued by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), seeks proposals for the NIH Tetramer Core Facility under solicitation number 75N93026R00006. The contract will support research and development activities related to major histocompatibility complex (MHC) tetramer reagents, requiring delivery of nine full-time equivalent personnel annually, including a Principal Investigator and technical staff. The period of performance spans a base year starting March 21, 2027, with options for up to six additional years, allowing continuation through March 20, 2034. The work will be performed primarily at NIH facilities in Bethesda, Maryland, with the Contractor responsible for packaging, shipping approximately 2,900 reagent shipments annually both domestically and internationally, and ensuring product integrity throughout. Proposals will be evaluated on a best value trade-off basis emphasizing technical merit over cost, with three main evaluation factors: technical approach, cost/price reasonableness and realism, and past performance. The technical evaluation prioritizes the technical plan (50%), personnel qualifications (20%), project management (20%), and facilities/resources (10%), with strict requirements for compliance with data management, accessibility (Section 508), and authentication standards. Cost proposals will be scrutinized for realism and balance, while past performance evaluations will focus on risk assessment and likelihood of successful contract execution. The contract type is cost-reimbursement based, featuring clauses such as inspection of research and development, termination for convenience specific to nonprofit institutions, and strict subcontracting plan requirements for non-small business offerors. Deliverables include detailed SOPs, licensing agreements, data management systems, and virtual workshops, all subject to formal government inspection and acceptance at the NIH Bethesda site. Special provisions prohibit the use of contract funds for pornography or gun control advocacy, while cybersecurity requirements mandate safeguarding federal contract information, including controls over access, malware protection, and incident reporting. The contract requires offerors to submit detailed representations and certifications via SAM.gov, including socio-economic status affirmations but with no small business set-aside. Submissions must be in specified formats with clear content limits and be delivered by the June 22, 2026 deadline. Payment will be managed through the Department of Treasury’s Invoice Processing Platform (IPP), with no use of WAWF authorized. The solicitation underscores the importance of maintaining reagent labeling with unique Research Resource Identifiers linked to database systems and compliance with NIH-specific packaging rather than military standards. Overall, this comprehensive solicitation outlines extensive technical, administrative,

General Info

NIH contract for Tetramer Core Facility providing MHC reagents, nine personnel, seven-year duration.

Agency

Department Of Health And Human Services → National Institutes Of Health Niaid

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

MD

Set-Aside

NONE

Documents

(2)

RFP 75N93026R00006 NIH Tetramer Core Facility

PDFrfp

Amendment 1 to RFP 75N93026R00006 NIH Tetramer Core Facility

PDFamendment

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

1 update
PhaseSolicitation
Type Changed

Presolicitation → Solicitation

Posted

Presolicitation

Amendment 2

Contract was updated

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid
Contacts2 people available
OfficeBETHESDA, MD, 20892, USA
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health Niaid
Office AddressBETHESDA, MD, 20892, USA

Full Description

Show more

Please see the attached PDF for the solicitation notice (75N93026R00006).


See Amendment #1 attached.

Similar Contracts

NAICS: 541714
New
Federal
TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.
Triad - DOE Contractor

POSTED

2 days ago

DEADLINE

in 6 months
View Details
NAICS: 541714
New
Federal
Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.
Defense Health Agency

POSTED

5 days ago

DEADLINE

in 1 day
View Details